Results 261 to 270 of about 9,559,132 (390)

Funding liquidation: a functional view [PDF]

open access: yes, 2006
Armour, J, Walters, A
core  

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Connecticut's substance use primary prevention resource assessment and interactive map initiative. [PDF]

open access: yesPublic Health Pract (Oxf)
Cunningham SD   +4 more
europepmc   +1 more source

Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest

open access: yesJAMA Internal Medicine, 2017
Susannah L. Rose   +3 more
semanticscholar   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy